Impact Factor
3.45
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.24
541 total citations
h5-index
25
h5 depth signal
Cited share
80.2%
142 of 177
Total citations
541
Citation footprint
Metric signal
2.33
External metric anchor
Self-citation
2.4%
13 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
478
India
149
United States
126
Iran
60
Italy
54
Citing Fields of Research
Oncology
335
Cancer & Development
305
Cancer, Autophagy & Apoptosis
216
Immunology
156
Lung Cancer
114
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,120
Articles tracked across the journal lifetime
Indexed publication set
177
142 cited publications
Last 12 months
188
15.7 publications/month
Open access share
3.2%
6 OA publications in the last year
Leading citing country
China
478 citing publications
Leading citing field
Oncology
335 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v1n1, May 2001-
v1n1, May 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cancer, Autophagy & Apoptosis
Oncology
Cancer & Development
Lung Cancer
Immunology
Noncoding RNA
Broad Categories
Antineoplastic Agents
Neoplasms
Cancer, Autophagy & Apoptosis
Immunology
Noncoding RNA
Lung Cancer
Cancer & Development
Cancer Drugs
DNA Damage
MeSH Descriptors
Drug Delivery Systems
Drug Design
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.2174/0115680096510085261008045702
Open DOI
Distinct Patterns and Earlier Onset of Adverse Events in Young vs. Non-Young Breast Cancer Patients: A Real-World Analysis
Introduction: Age-related differences in Adverse Event (AE) reporting and reported Time to Onset (TTO) during systemic breast cancer treatment remain poorly characterized. Methods: We analyzed deduplicated reports from the U.S. Food and ...
02
DOI 10.2174/0115680096497180260909094944
Open DOI
Single-Cell Transcriptomics Identifies Fibroblast-Associated Transcriptional Patterns and Candidate Therapeutic Targets in the Comorbidity of Non-Small Cell Lung Cancer and Obesity
Background/Introduction: Obesity acts as a critical modifiable risk factor for non-small cell lung cancer (NSCLC), while the key cellular and molecular drivers mediating their comorbid association remain poorly defined. Single-cell RNA s...
03
DOI 10.2174/0115680096474148261006093302
Open DOI
Hypoxia-Responsive Co-Loaded Liposomal Drug Delivery System for the Treatment of Breast Cancer
Aim: A hypoxia-responsive drug-loaded liposomal drug delivery system was designed with the aim of effective treatment of breast cancer. This involves the synthesis and characterization of a nitroimidazole derivative incorporated within t...
04
DOI 10.2174/0115680096481382261002063656
Open DOI
Evolving Molecular Drug Targets in Pancreatic Cancer: An Updated Review
Pancreatic Cancer (PC) remains one of the most aggressive and lethal malignancies with an extremely low survival rate. Existing conventional therapies such as surgery, chemotherapy, radiotherapy, and immunotherapy have demonstrated limit...
05
DOI 10.2174/0115680096496235261002093852
Open DOI
Neurotransmitters and Drug Repurposing in Cancer Therapy: Targeting the Nervous System for Tumor Suppression
Emerging research indicates that the nervous system plays a complex role in cancer, with neurotransmitters regulating tumour growth, immune evasion, and resistance to therapy. It has been reported that several important oncogenic pathway...
06
DOI 10.2174/0115680096507014261001062033
Open DOI
Supplementation with Akkermansia muciniphila Enhances the αPD-1 Efficacy in Mice Transplanted with Gut Microbiota from Patients with Colorectal Cancer
Introduction: The resistance of colorectal cancer (CRC) to PD-1 blockade has positioned it as a critical focus of global research efforts. The gut microbiota is a key regulator of anti-tumor immunity, but research on bacteria that are cl...
07
DOI 10.2174/0115680096476681260927132043
Open DOI
Translational Horizons in Targeted Oncology: Mechanistic Insights, Therapeutic Innovations, and Clinical Impact
Introduction: Because of the elevated prevalence and death rates of cancers such as breast, lung, colorectal, bladder, gastrointestinal, and liver malignancies, cancer remains an important global health issue. More productive, targeted, ...
08
DOI 10.2174/0115680096498489260907114046
Open DOI
Barrier Function and Tight Junctions in Tyrosine Kinase Inhibitor-Induced Diarrhoea: A Scoping Review
Introduction: Tyrosine Kinase Inhibitors (TKIs) are widely used in modern cancer treatment and have significantly improved outcomes for many patients. However, their use is frequently limited by gastrointestinal side effects, particularl...
09
DOI 10.2174/0115680096488328260909072155
Open DOI
Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway
Introduction: EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Gefitinib (GEF), as a first-generation EGFR-TKI, has made significant progress in the treatm...
10
DOI 10.2174/0115680096457176260827075822
Open DOI
MicroRNA-23C Impacts Hepatocellular Carcinoma Metastasis by Targeting OTUB1
Background: MicroRNA-23C (miR-23C) and Ovarian Tumor domain-contain-ing Ubiquitin Aldehyde-Binding protein 1 (OTUB1) have been crucially implicated in nu-merous malignancies, such as Hepatocellular Carcinoma (HCC), a common malignant tu-...
Bibliographical & Catalog Notes
Title from cover.
Also available online.